Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis

被引:61
作者
Baker, Joshua F. [1 ,2 ]
Conaghan, Philip G. [3 ,4 ]
Smolen, Josef S. [5 ]
Aletaha, Daniel [5 ]
Shults, Justine [1 ]
Emery, Paul [6 ,7 ]
Baker, Daniel G. [8 ]
Ostergaard, Mikkel [9 ,10 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Philadelphia VA Med Ctr, Philadelphia, PA USA
[3] Univ Leeds, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[4] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[5] Med Univ Vienna, Vienna, Austria
[6] Univ Leeds, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds Inst Rheumat & Musculoskeletal Med, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[7] Chapel Allerton Hosp, Leeds, W Yorkshire, England
[8] Janssen Res & Dev LLC, Spring House, PA USA
[9] Glostrup Cty Hosp, Copenhagen, Denmark
[10] Univ Copenhagen, Copenhagen, Denmark
关键词
NECROSIS-FACTOR-ALPHA; METHOTREXATE THERAPY; CLINICAL-PRACTICE; ACTIVITY INDEX; DOUBLE-BLIND; GO-FORWARD; PHASE-III; GOLIMUMAB; ANTIBODY; VALIDITY;
D O I
10.1002/art.38304
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To develop and validate composite disease activity scores, based on widely available clinical measures, that would demonstrate improved correlation with detection of synovitis on magnetic resonance imaging (MRI) and radiographic progression, in comparison with conventional measures, in patients with rheumatoid arthritis (RA). Methods. This study was conducted as a secondary study of 2 RA clinical trials, GO-BEFORE (development cohort) and GO-FORWARD (validation cohort). Generalized estimating equations were used to evaluate independent cross-sectional associations of component variables (from all time points) with concurrent MRI measures of synovitis and bone edema in the development cohort. Based on regression coefficients, modified versions of the Disease Activity Score in 28 joints (M-DAS28), Simplified Disease Activity Index (M-SDAI), and Clinical Disease Activity Index (M-CDAI) were generated for each subject in the validation cohort. The M-DAS28, M-SDAI, and M-CDAI scores were compared to conventional scores of disease activity with regard to associations with MRI measures of synovitis and radiographic progression, assessed using Pearson's and Spearman's correlations, linear/logistic regression, and receiver operating characteristic analysis. Results. Four variables were independently associated with MRI-detected synovitis and bone edema in the development cohort: C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), swollen joint count in 28 joints (SJC28), and evaluator's global assessment of disease activity using a visual analog scale (EvGA score). Modified disease activity scores were generated using the regression coefficients obtained in the synovitis models for all subjects in the validation cohort; modified scores were calculated as M-DAS28 x 0.49 x ln(CRP) + 0.15 x SJC28 + 0.22 x EvGA + 1 and M-SDAI = CRP + SJC28 + EvGA. Both modified and conventional disease activity scores correlated significantly with MRI measures of synovitis. Modified scores showed superior correlation with synovitis, as compared to conventional scores, at all time points (P < 0.05). Furthermore, the M-DAS28 and M-SDAI had superior test characteristics for prediction of radiographic progression at 52 weeks (both P < 0.05). Conclusion. Modified disease activity scores demonstrated superior correlation with MRI detection of synovitis at all time points, and more accurately predicted radiographic progression in patients with RA in a clinical trial setting.
引用
收藏
页码:794 / 802
页数:9
相关论文
共 17 条
[1]   The definition and measurement of disease modification in inflammatory rheumatic diseases [J].
Aletaha, D ;
Smolen, JS .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2006, 32 (01) :9-+
[2]  
Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
[3]  
BAKER JF, 2013, ANN RHEUM DIS
[4]   The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy [J].
Emery, Paul ;
Fleischmann, Roy ;
van der Heijde, Desiree ;
Keystone, Edward C. ;
Genovese, Mark C. ;
Conaghan, Philip G. ;
Hsia, Elizabeth C. ;
Xu, Weichun ;
Baratelle, Anna ;
Beutler, Anna ;
Rahman, Mahboob U. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (05) :1200-1210
[5]   Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis [J].
Emery, Paul ;
Fleischmann, Roy M. ;
Moreland, Larry W. ;
Hsia, Elizabeth C. ;
Strusberg, Ingrid ;
Durez, Patrick ;
Nash, Peter ;
Amante, Eric Jason B. ;
Churchill, Melvin ;
Park, Won ;
Antonio Pons-Estel, Bernardo ;
Doyle, Mittie K. ;
Visvanathan, Sudha ;
Xu, Weichun ;
Rahman, Mahboob U. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2272-2283
[6]   Evaluating disease activity in rheumatoid arthritis: Which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI [J].
Gaujoux-Viala, Cecile ;
Mouterde, Gael ;
Baillet, Athan ;
Claudepierre, Pascal ;
Fautrel, Bruno ;
Le Loet, Xavier ;
Maillefert, Jean-Francis .
JOINT BONE SPINE, 2012, 79 (02) :149-155
[7]   Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [J].
Keystone, E. C. ;
Genovese, M. C. ;
Klareskog, L. ;
Hsia, E. C. ;
Hall, S. T. ;
Miranda, P. C. ;
Pazdur, J. ;
Bae, S-C ;
Palmer, W. ;
Zrubek, J. ;
Wiekowski, M. ;
Visvanathan, S. ;
Wu, Z. ;
Rahman, M. U. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :789-796
[8]   Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study [J].
Keystone, Edward ;
Genovese, Mark C. ;
Klareskog, Lars ;
Hsia, Elizabeth C. ;
Hall, Stephen ;
Miranda, Pedro C. ;
Pazdur, Jacek ;
Bae, Sang-Cheol ;
Palmer, William ;
Xu, Stephen ;
Rahman, Mahboob U. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :1129-1135
[9]   Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study [J].
Kremer, Joel ;
Ritchlin, Christopher ;
Mendelsohn, Alan ;
Baker, Daniel ;
Kim, Lilianne ;
Xu, Zhenhua ;
Han, John ;
Taylor, Peter .
ARTHRITIS AND RHEUMATISM, 2010, 62 (04) :917-928
[10]   Quantification of synovitis by MRI: Correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation [J].
Ostergaard, M ;
Stoltenberg, M ;
Lovgreen-Nielsen, P ;
Volck, B ;
Sonne-Holm, S ;
Lorenzen, I .
MAGNETIC RESONANCE IMAGING, 1998, 16 (07) :743-754